Mirati Therapeutics, Inc. (NASDAQ:MRTX) CFO Jamie A. Donadio sold 12,100 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $35.00, for a total value of $423,500.00. Following the sale, the chief financial officer now owns 12,100 shares in the company, valued at $423,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) opened at $33.90 on Wednesday. The stock has a market capitalization of $1,011.46, a P/E ratio of -12.15 and a beta of 2.06. Mirati Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $37.62.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.06). equities analysts forecast that Mirati Therapeutics, Inc. will post -2.46 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in Mirati Therapeutics by 68.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock valued at $3,939,000 after buying an additional 137,104 shares in the last quarter. Artal Group S.A. acquired a new stake in Mirati Therapeutics in the 4th quarter valued at $1,825,000. SG Americas Securities LLC acquired a new stake in Mirati Therapeutics in the 4th quarter valued at $829,000. Citadel Advisors LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at $268,000. Finally, Jane Street Group LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at $668,000. 82.89% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2018/03/14/mirati-therapeutics-inc-mrtx-cfo-jamie-a-donadio-sells-12100-shares.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.